Mundipharma Acquires Cinfa Biotech for Expansion of its Biosimilar Portfolio

 Mundipharma Acquires Cinfa Biotech for Expansion of its Biosimilar Portfolio

Mundipharma Acquires Cinfa Biotech for Expansion of its Biosimilar Portfolio

Shots:

  • Mundipharma acquires all shares of the parent company of Cinfa, Infarco including Pelmeg (pegfilgrastim, biosimilar) having global market value $4.5B
  • The acquisition focuses on expansion of biosimilar platform by developing multiple biosimilars indicated across various therapy areas
  • Pelmeg is a granulocyte-colony stimulating factor (GCSF) used for the treatment of CT-induced neutropenia and also received CHMP approval on 20th Sep, 2018

Click here to read full press release/ article | Ref: Mundipharma | Image: Pro Biosimilars 

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post